Treatment of HER2-positive metastatic breast cancer
- PMID: 25970056
- PMCID: PMC4980989
- DOI: 10.1056/NEJMc1503446
Treatment of HER2-positive metastatic breast cancer
Conflict of interest statement
Since publication of their article, the authors report no further potential conflict of interest.
Comment on
-
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. N Engl J Med. 2015. PMID: 25693012 Free PMC article. Clinical Trial.
-
Treatment of HER2-positive metastatic breast cancer.N Engl J Med. 2015 May 14;372(20):1964. doi: 10.1056/NEJMc1503446. N Engl J Med. 2015. PMID: 25970057 No abstract available.
References
-
- Tripathy D, Brufsky A, Cobleigh M, et al. Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: early results from the Systemic therapies for HER2-positive metastatic breast cancer registry study. Presented at the 37th Annual San Antonio Breast Cancer Symposium; San Antonio, TX. December 9–13 2014; abstract.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous